Thus, CCL18 and/or its potential receptor PITPNM3 may serve as therapeutic targets for inhibiting angiogenesis in breast cancer, particularly for patients with resistance to anti-VEGF monotherapy. This evidence concerns the gene CCL18 and breast carcinoma.